Risk of herpes zoster in patients prescribed inhaled corticosteroids: A cohort study

BMC Pulmonary Medicine

Volumn 11, Issue , 2011, Pages

  Ernst, Pierre ^a,b   Dell'Aniello, Sophie ^a,b   Mikaeloff, Yann ^a,b   Suissa, Samy ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Adverse drug effects; Cytochrome p450; Herpes zoster; Inhaled corticosteroids; Observational studies

Indexed keywords

AMIODARONE; APREPITANT; BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CIPROFLOXACIN; CLARITHROMYCIN; CORTICOSTEROID; CROMOGLYCATE DISODIUM; DELAVIRDINE; DILTIAZEM; ERYTHROMYCIN; FLUNISOLIDE; FLUOXETINE; FLUTICASONE; IMATINIB; INDINAVIR; ISONIAZID; ITRACONAZOLE; KETOCONAZOLE; NEFAZODONE; NELFINAVIR; NORFLOXACIN; RITONAVIR; SAQUINAVIR; TAMOXIFEN; TRIAMCINOLONE; VERAPAMIL; VORICONAZOLE; ANTIASTHMATIC AGENT; CYTOCHROME P450;

ADULT; ARTICLE; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; CORTICOSTEROID THERAPY; FEMALE; HERPES ZOSTER; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; ASTHMA; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; INHALATIONAL DRUG ADMINISTRATION; RISK;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA; CASE-CONTROL STUDIES; COHORT STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HERPES ZOSTER; HUMANS; MALE; PRESCRIPTIONS; RISK;

EID: 83455186358     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/1471-2466-11-59     Document Type: Article

References (23)

1. Hubbard RB, Smith CJ, Smeeth L, Harrison TW, Tattersfield AE. Inhaled corticosteroids and hip fracture: a population-based case-control study. Am J Respir Crit Care Med 2002, 166:1563-1566. 10.1164/rccm.200206-606OC, 12406825.
2. Garbe E, Suissa S, LeLorier J. Association of inhaled corticosteroid use with cataract extraction in elderly patients. JAMA 1998, 280:539-543. 10.1001/jama.280.6.539, 9707144.
3. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007, 356:775-789. 10.1056/NEJMoa063070, 17314337.
4. Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007, 176:162-166. 10.1164/rccm.200611-1630OC, 17400730.
5. Saag KG, Koehnke R, Caldwell JR, Brasington R, Burmeister LF, Zimmerman B, Kohler JA, Furst DE. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 1994, 96:115-123. 10.1016/0002-9343(94)90131-7, 8109596.
6. Sagir A, Schmitt M, Dilger K, Haussinger D. Inhibition of cytochrome P450 3A: relevant drug interactions in gastroenterology. Digestion 2003, 68:41-48. 10.1159/000073224, 12949438.
7. Murray M. Mechanisms and significance of inhibitory drug interactions involving cytochrome P450 enzymes (review). Int J Mol Med 1999, 3:227-238.
8. Thomas SL, Hall AJ. What does epidemiology tell us about risk factors for herpes zoster?. Lancet Infect Dis 2004, 4:26-33. 10.1016/S1473-3099(03)00857-0, 14720565.
9. Brisson M, Edmunds WJ, Law B, Gay NJ, Walld R, Brownell M, Roos L, de Serres G. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect 2001, 127:305-314. 2869750, 11693508.
10. Cunningham AL, Dworkin RH. The management of post-herpetic neuralgia. Br Med J 2000, 321:778-779.
11. Lawrenson R, Williams T, Farmer R. Clinical information for research; the use of general practice databases. J Public Health Med 1999, 21:299-304. 10.1093/pubmed/21.3.299, 10528957.
12. Walley T, Mantgani A. The UK General Practice Research Database [see comments]. Lancet 1997, 350:1097-1099. 10.1016/S0140-6736(97)04248-7, 10213569.
13. Garcia Rodriguez LA, Perez GS. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 1998, 45:419-425. 1873548, 9643612.
14. Mikaeloff Y, Kezouh A, Suissa S. Nonsteroidal anti-inflammatory drug use and the risk of severe skin and soft-tissue complications in patients with varivella or zoster disease. Br J Clin Pharmac 2008, 65:203-209.
15. National Asthma and Prevention Program Guidelines for the diagnosis and management of asthma. Expert Panel Report 2 1997, National Heart LaBI, NIH Publication No. 97-4051, National Asthma and Prevention Program.
16. Boulet L-P, Becker A, Bérubé D, Beveridge R, Ernst P. Summary of recommendations from the asthma consensus report, 1999. Can Med Assoc J 1999, 161:s1-s62.
17. Wertheimer AI. The defined daily dose system (DDD) for drug utilization review. Hosp Pharm 1986, 21:233-41. 258.
18. Lipworth BJ, Jackson CM. Safety of inhaled and intranasal corticosteroids: lessons for the new millennium. Drug Saf 2000, 23:11-33. 10.2165/00002018-200023010-00002, 10915030.
19. Jick SS, Kaye JA, Vasilakis-Scaramozza C, Garcia Rodriguez LA, Ruigomez A, Meier CR, Schlienger RG, Black C, Jick H. Validity of the general practice research database. Pharmacotherapy 2003, 23:686-689. 10.1592/phco.23.5.686.32205, 12741446.
20. Moride Y, Abenhaim L. Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research. J Clin Epidemiol 1994, 47:731-737. 10.1016/0895-4356(94)90170-8, 7722586.
21. McDonald JR, Zeringue AL, Caplan L, Ranganathan P, Xian H, Burroughs TE, Fraser VJ, Cunningham F, Eisen SA. Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis. Clin Infect Dis 2009, 48:1364-1371. 10.1086/598331, 2743911, 19368499.
22. Yang YW, Chen YH, Wang KH, Wang CY, Lin HW. Risk of herpes zoster among patients with chronic obstructive pulmonary disease: a population-based study. CMAJ 2011, 183:E275-E280. 10.1503/cmaj.101137, 3060212, 21343261.
23. Heymann AD, Chodick G, Karpati T, Kamer L, Kremer E, Green MS, Kokia E, Shalev V. Diabetes as a risk factor for herpes zoster infection: results of a population-based study in Israel. Infection 2008, 36:226-230. 10.1007/s15010-007-6347-x, 18454342.